Hot Features
プレミアム
BLACK FRIDAY
25周年を記念 1999-2024
Forexで最大60%オフ
1年間40％、2年間40％、*3年間60％
リアルタイム株価 | レベル2 | |
|---|---|---|
Forex |
*3年間で¥ 153396、たったの¥ 61358
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical t... Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California. 詳細を表示
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with...
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...
SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.29 | -9.83050847458 | 2.95 | 3 | 2.33 | 155863 | 2.44855145 | CS |
| 4 | -0.34 | -11.3333333333 | 3 | 3.75 | 2.33 | 97216 | 2.82864609 | CS |
| 12 | -0.98 | -26.9230769231 | 3.64 | 4.72 | 2.33 | 72187 | 3.11999756 | CS |
| 26 | -8.81 | -76.8090671316 | 11.47 | 11.87 | 2.33 | 80040 | 4.0698723 | CS |
| 52 | -57.31 | -95.5644488911 | 59.97 | 59.97 | 2.33 | 68346 | 7.24489471 | CS |
| 156 | -57.31 | -95.5644488911 | 59.97 | 59.97 | 2.33 | 22782 | 7.24489471 | CS |
| 260 | -26.77 | -90.9616038056 | 29.43 | 60 | 2.33 | 81603 | 48.78618797 | CS |
BDEZ
4分前
$GROO
4分前
Oleblue
5分前
JettaR
6分前
lambchops
6分前
reaper247
8分前
jondoeuk
9分前
skitahoe
9分前
jjjjjjjj
10分前
jondoeuk
10分前
gfp927z
12分前
jondoeuk
12分前
Plato_
17分前
gimmegimmeminemine
18分前
rrflyboy
19分前
jondoeuk
19分前
dinogreeves
19分前
XenaLives
19分前
jimmy051357
20分前
DJPele
20分前
hardlesson
21分前
dinogreeves
22分前
TrendTrade2016
23分前
TrendTrade2016
25分前
holter49
26分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
